藥學雜誌電子報137期 | 合法藥品大搜索

2018年12月31日—...全部白血病人的15%，男女比例約為1.4：1；根據台灣癌症基金會指出，每年台灣新...Bosutinib為第二代酪胺酸激酶抑制劑，其基因選擇性為imatinib ...

You-An Shih, Wen-Hsun Lee, Hui-Chuan Hsiao, Hsiu-Mei Chang, Wei-Hsuan Huang Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. Tyrosine kinase inhibitors (TKIs) are the initial targeted therapies for CML. Imatinib is the first generation of TKI which has been proven to be effective in BCR-ABL tyrosine kinase. As a result of mutations in the kinase domain of BCR-ABL, the second and the third generation of TKIs have been developed, such as nilotinib, dasatinib, bosutinib, ponatinib. They are approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML. There are different selectivities for BCR-ABL, and different side effects for TKIs’. Appropriate medications could be chosen based on the need of patients’ spec...